August 6, 2007
Eisai Co., Ltd. announced on July 27 that it has obtained from Sepracor Inc. exclusive rights to develop and market the insomnia treatment eszopiclone (US brand name: LUNESTA) in Japan. In Japan, more than 24 million people are reported to...read more